Drugs / Regulatory T-cell enriched infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03683498 | Sep 2018 → Mar 2022 | chronic graft versus host disease | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regulatory T-cell enriched infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03683498 ↗ |
| Known as | Treg | “We conducted phase 1 dose-escalation clinical trials testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory/dependent cGVHD.” PMID 41637631 ↗ May 2026 |
| Modality | Cell therapy | “freshly isolated donor-derived Treg infusions” PMID 41637631 ↗ May 2026 |